Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eight-week interval in flushing and locking port-a-cath in cancer patients: A single-institution experience and systematic review.
Fornaro C, Piubeni M, Tovazzi V, Cosentini D, Gelmi M, Rota G, Berta B, Barucco W, Lombardi E, Moles L, Faustini T, Fettolini T, Motta P, Ferrari VD, Berruti A, Conti E. Fornaro C, et al. Among authors: berruti a. Eur J Cancer Care (Engl). 2019 Mar;28(2):e12978. doi: 10.1111/ecc.12978. Epub 2018 Dec 10. Eur J Cancer Care (Engl). 2019. PMID: 30536872
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance.
Grisanti S, Almici C, Consoli F, Buglione M, Verardi R, Bolzoni-Villaret A, Bianchetti A, Ciccarese C, Mangoni M, Ferrari L, Biti G, Marini M, Ferrari VD, Nicolai P, Magrini SM, Berruti A. Grisanti S, et al. Among authors: berruti a. PLoS One. 2014 Aug 8;9(8):e103918. doi: 10.1371/journal.pone.0103918. eCollection 2014. PLoS One. 2014. PMID: 25105871 Free PMC article.
Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients.
Bedussi F, Valcamonico F, Mosca A, Sigala S, Ferrari L, Terrone C, Volta AD, Marchioro G, Ferrari V, Alabiso O, Memo M, Berruti A. Bedussi F, et al. Among authors: berruti a. Endocrine. 2016 Dec;54(3):830-833. doi: 10.1007/s12020-015-0827-z. Epub 2015 Dec 21. Endocrine. 2016. PMID: 26690656 No abstract available.
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature.
Grisanti S, Ferrari VD, Buglione M, Agazzi GM, Liserre R, Poliani L, Buttolo L, Gipponi S, Pedersini R, Consoli F, Panciani P, Roca E, Spena G, Triggiani L, Berruti A; Gruppo Neuro-Oncologico Bresciano. Grisanti S, et al. Among authors: berruti a. J Neurosurg Sci. 2019 Aug;63(4):458-467. doi: 10.23736/S0390-5616.16.03874-1. Epub 2016 Sep 28. J Neurosurg Sci. 2019. PMID: 27680966
520 results